ProPhase BioPharma

ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing and development of novel drugs, compounds and biotechnology. ProPhase obtained exclusive rights worldwide to develop and commercialize Equivir (OTC/Dietary Supplement) and Equivir G (Rx). PBIO also executed a license agreement for the Linebacker portfolio (LB-1 and LB-2), two patented small molecule PIM kinase inhibitors with significant potential across multiple therapeutic indications. LB-1 is designed as an anti-cancer agent to be used as a co-therapy that targets PIM kinase receptors, a growth factor expressed in cancer.